MX348798B - Composicion farmaceutica que contiene copolimero en bloque que comprende compuesto de acido boronico. - Google Patents

Composicion farmaceutica que contiene copolimero en bloque que comprende compuesto de acido boronico.

Info

Publication number
MX348798B
MX348798B MX2013010234A MX2013010234A MX348798B MX 348798 B MX348798 B MX 348798B MX 2013010234 A MX2013010234 A MX 2013010234A MX 2013010234 A MX2013010234 A MX 2013010234A MX 348798 B MX348798 B MX 348798B
Authority
MX
Mexico
Prior art keywords
atoms
pharmaceutical composition
boron
block copolymer
bond
Prior art date
Application number
MX2013010234A
Other languages
English (en)
Other versions
MX2013010234A (es
Inventor
Saito Hiroyuki
Kobayashi Katsutoshi
Tanaka Ryosuke
Harada Mitsunori
Kato Yasuki
Original Assignee
Nanocarrier Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocarrier Co Ltd filed Critical Nanocarrier Co Ltd
Publication of MX2013010234A publication Critical patent/MX2013010234A/es
Publication of MX348798B publication Critical patent/MX348798B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)

Abstract

La presente invención proporciona una composición farmacéutica. La composición farmacéutica incluye un copolímero en bloque que incluye: un segmento hidrofílico; un segmento hidrofóbico y un compuesto de ácido borónico unido a una cadena lateral del segmento hidrofóbico vía una fracción del conector que incluye una estructura heterocíclica, en donde: un esqueleto cíclico de la estructura heterocíclica tiene un átomo de boro derivado del compuesto de ácido borónico, los átomos de X unidos al átomo de boro y cada uno es seleccionado de un átomo de oxígeno y un átomo de nitrógeno, y los átomos de carbono unidos a los átomos de X; y el copolímero en bloque comprende además un grupo orgánico unido a los átomos de carbono, el grupo orgánico que contiene un grupo aromático o un grupo alquilo cíclico como una estructura para proteger un enlace de éster de ácido borónico y/o un enlace de la amida de boro que resulta entre el átomo de boro y los átomos de X.
MX2013010234A 2011-03-31 2012-04-02 Composicion farmaceutica que contiene copolimero en bloque que comprende compuesto de acido boronico. MX348798B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011080509 2011-03-31
PCT/JP2012/058831 WO2012133884A1 (ja) 2011-03-31 2012-04-02 ボロン酸化合物を含有したブロック共重合体を含む医薬組成物

Publications (2)

Publication Number Publication Date
MX2013010234A MX2013010234A (es) 2014-03-31
MX348798B true MX348798B (es) 2017-06-29

Family

ID=46931571

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010234A MX348798B (es) 2011-03-31 2012-04-02 Composicion farmaceutica que contiene copolimero en bloque que comprende compuesto de acido boronico.

Country Status (12)

Country Link
US (1) US9561284B2 (es)
EP (1) EP2692777B1 (es)
JP (1) JP5086497B1 (es)
KR (1) KR101869125B1 (es)
CN (1) CN103502319B (es)
AU (1) AU2012233171B2 (es)
BR (1) BR112013025005A2 (es)
CA (1) CA2828700A1 (es)
MX (1) MX348798B (es)
RU (1) RU2569847C2 (es)
TW (1) TWI533885B (es)
WO (1) WO2012133884A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103502319B (zh) 2011-03-31 2015-11-25 那野伽利阿株式会社 包含含有硼酸化合物的嵌段共聚物的医药组合物
ES2603632T3 (es) 2011-11-17 2017-02-28 The University Of Tokyo Copolímero en bloque que tiene un grupo ácido fenilborónico introducido en el mismo, y usos del mismo
US20160129117A1 (en) * 2013-07-03 2016-05-12 Nippon Kayaku Kabushiki Kaisha Novel Boronic Acid Compound Preparation
JP6566936B2 (ja) 2014-05-08 2019-08-28 国立大学法人 東京大学 医薬組成物
US20180243217A1 (en) * 2015-03-17 2018-08-30 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
JPWO2017164334A1 (ja) * 2016-03-23 2019-02-28 公益財団法人川崎市産業振興財団 ホウ素クラスター結合ペプチド化合物
JP7387330B2 (ja) * 2019-08-09 2023-11-28 東和薬品株式会社 ボルテゾミブ保存用容器

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3257029B2 (ja) 1992-04-22 2002-02-18 日本油脂株式会社 フェニルボロン酸誘導体及び製造方法
JPH083172A (ja) 1994-06-15 1996-01-09 Nippon Oil & Fats Co Ltd フェニルボロン酸誘導体および製造方法
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JP2002179683A (ja) 2000-12-13 2002-06-26 Japan Science & Technology Corp ポリアミノ酸誘導体から成る核酸関連物質反応試薬
KR100982933B1 (ko) * 2003-12-10 2010-09-17 가부시키가이샤 도쿄다이가쿠 티엘오 디아미노시클로헥산 백금 (ⅱ) 과폴리(카르복실산)세그먼트 함유 블록 공중합체의 배위착물, 그 항종양제
EP2077293B1 (en) * 2006-10-19 2011-04-20 NanoCarrier Co., Ltd. Block copolymer for drug conjugates and their pharmaceutical compositions
JP2010519305A (ja) * 2007-02-26 2010-06-03 ウィスコンシン・アルムニ・リサーチ・ファウンデーション 併用薬物送達のためのポリマー性ミセル
WO2009133647A1 (ja) 2008-05-02 2009-11-05 国立大学法人筑波大学 高分子化環状二トロキシドラジカル化合物およびその使用
CA2695611C (en) * 2008-07-29 2011-02-01 Nanocarrier Co., Ltd. Active targeting polymer micelle encapsulating drug, and pharmaceutical composition
WO2010019718A2 (en) 2008-08-13 2010-02-18 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
JP5622188B2 (ja) 2010-01-05 2014-11-12 独立行政法人物質・材料研究機構 フェニルボロン酸系単量体及びフェニルボロン酸系重合体
JP2011173960A (ja) 2010-02-23 2011-09-08 Univ Of Tsukuba 高分子ミセル型光刺激応答性一酸化窒素供与体
CN103502319B (zh) 2011-03-31 2015-11-25 那野伽利阿株式会社 包含含有硼酸化合物的嵌段共聚物的医药组合物
CN102391504B (zh) * 2011-09-05 2013-05-15 中国科学院长春应用化学研究所 共聚物、葡萄糖敏感胶束、葡萄糖敏感载药胶束及其制备方法
ES2603632T3 (es) 2011-11-17 2017-02-28 The University Of Tokyo Copolímero en bloque que tiene un grupo ácido fenilborónico introducido en el mismo, y usos del mismo
CN104508863B (zh) * 2012-07-30 2017-04-19 帝人株式会社 非水电解质电池用隔膜及非水电解质电池

Also Published As

Publication number Publication date
RU2569847C2 (ru) 2015-11-27
MX2013010234A (es) 2014-03-31
AU2012233171A1 (en) 2013-09-19
BR112013025005A2 (pt) 2017-01-17
CN103502319B (zh) 2015-11-25
EP2692777B1 (en) 2018-10-31
AU2012233171B2 (en) 2015-08-20
TWI533885B (zh) 2016-05-21
JP5086497B1 (ja) 2012-11-28
RU2013148535A (ru) 2015-05-10
US20140017192A1 (en) 2014-01-16
CN103502319A (zh) 2014-01-08
KR20140038376A (ko) 2014-03-28
EP2692777A4 (en) 2014-11-05
US9561284B2 (en) 2017-02-07
WO2012133884A1 (ja) 2012-10-04
TW201244739A (en) 2012-11-16
JPWO2012133884A1 (ja) 2014-07-28
CA2828700A1 (en) 2012-10-04
KR101869125B1 (ko) 2018-06-19
EP2692777A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
MX348798B (es) Composicion farmaceutica que contiene copolimero en bloque que comprende compuesto de acido boronico.
PH12016501822A1 (en) Cyclopropaneamine compound
IN2014DN10723A (es)
CR20190465A (es) COMPOSICIONES PARA EL CONTROL DE PLAGAS QUE INCLUYE UN DERIVADO DE IMINOPIRIDINA NOVEDOSO (Divisional 2014-0450)
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
TW201129556A (en) Novel antiplatelet agent
UA102543C2 (uk) Феніл- та бензодіоксинілзаміщені похідні імідазолів
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
UA114656C2 (uk) Похідні піридину
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
MY162601A (en) Curable epoxy resin composition
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2014013660A (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
IN2012DN05467A (es)
MD4602B1 (ro) Inhibitori ai virusului hepatic C
NZ593951A (en) Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
IN2014CN03976A (es)
EA201270216A1 (ru) Фармацевтический состав
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
IN2014DN08150A (es)
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
MX360330B (es) Regimen de administracion para nitrocatecoles.
MY170262A (en) Dicarboxylic acid compound
MX2013010962A (es) Nuevos derivados de furanona.

Legal Events

Date Code Title Description
FG Grant or registration